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Inactivation-mimicking block of the epithelial calcium 
channel TRPV6
Rajesh Bhardwaj1*, Sonja Lindinger2*, Arthur Neuberger3*, Kirill D. Nadezhdin3*,  
Appu K. Singh3,4, Micael R. Cunha5, Isabella Derler2, Gergely Gyimesi1, Jean-Louis Reymond5, 
Matthias A. Hediger1†, Christoph Romanin2†, Alexander I. Sobolevsky3†
Epithelial calcium channel TRPV6 plays vital roles in calcium homeostasis, and its dysregulation is implicated in multi-
factorial diseases, including cancers. Here, we study the molecular mechanism of selective nanomolar- affinity 
TRPV6 inhibition by (4-phenylcyclohexyl)piperazine derivatives (PCHPDs). We use x-ray crystallography and 
cryo–electron microscopy to solve the inhibitor-bound structures of TRPV6 and identify two types of inhibitor 
binding sites in the transmembrane region: (i) modulatory sites between the S1-S4 and pore domains normally 
occupied by lipids and (ii) the main site in the ion channel pore. Our structural data combined with muta-
genesis, functional and computational approaches suggest that PCHPDs plug the open pore of TRPV6 and con-
vert the channel into a nonconducting state, mimicking the action of calmodulin, which causes inactivation of TRPV6 
channels under physiological conditions. This mechanism of inhibition explains the high selectivity and potency 
of PCHPDs and opens up unexplored avenues for the design of future-generation biomimetic drugs.
INTRODUCTION
Transient receptor potential (TRP) channels are transmembrane 
(TM) proteins that mediate the flux of monovalent and divalent 
ions across biological membranes (1). TRP channels are associated 
with a variety of genetic and acquired diseases and investigated as 
important drug targets (2). TRPV6, a member of the vanilloid sub-
family of TRP channels, is a cation-permeable epithelial channel 
that is highly selective to calcium (3). Since TRPV6 is the principal 
calcium uptake channel that captures diet-delivered Ca2+ ions in the 
gut, it is involved in the whole-body calcium homeostasis. As a con-
sequence, it plays an important role in maternal-fetal Ca2+ trans-
port (4, 5) and bone homeostasis (6), while mutations in TRPV6 are 
linked to transient neonatal hyperparathyroidism (7) as well as un-
dermineralization and dysplasia (8) of the human skeleton. In addi-
tion, changes in TRPV6 expression have been detected in several 
mouse models of human diseases, including Pendred syndrome, 
Crohn’s-like disease, Lowe syndrome, Dent disease, Gitelman syn-
drome, and kidney stone disease (3). Because of the central role of 
calcium in the development of cancer (9), TRPV6 has also been 
classified as an oncochannel (10). TRPV6 is overexpressed in vari-
ous types of human cancer cells, including breast, prostate, colon, 
ovarian, thyroid, endometrial, and leukemia cancer cells (9, 11). 
Furthermore, in 93% of biopsies, the levels of TRPV6 were elevated 
more in invasive compared to noninvasive tumor areas (12). Corre-
spondingly, TRPV6 inhibitors can potentially be used for the treat-
ment of a broad range of diseases associated with disturbed calcium 
homeostasis, including TRPV6-rich tumors (13–16).
Several small-molecule inhibitors of TRPV6, including 
2-aminoethoxydiphenyl borate (2-APB; IC50 = 71 M), have been 
identified, but the majority either are nonspecific or have low 
potency (17–21). In contrast, we developed the first small-molecule 
TRPV6 inhibitors, (4-phenylcyclohexyl)piperazine derivatives 
(PCHPDs), that are highly selective and have nanomolar affinity 
(21–23). Here, we solve x-ray and cryo–electron microscopy (cryo-EM) 
structures of TRPV6 in complex with several PCHPD inhibitors and 
identify PCHPD binding sites in the channel’s TM domain. Combining 
our structural data with mutagenesis and biochemical, functional, and 
computational approaches, we investigate the mechanism of TRPV6 
inhibition by PCHPDs. Unprecedented for TRP channels, PCHPDs 
mimic the action of calmodulin (CaM), which causes inactivation of 
TRPV6 channels under physiological conditions (24, 25). This inhibi-
tion mechanism explains the high selectivity and potency of PCHPDs 
and can be used as a guide for structure- based drug design.
RESULTS AND DISCUSSION
Functional characterization of TRPV6 inhibition by PCHPDs
Currents through human TRPV6 (hTRPV6) channels transiently 
expressed in human embryonic kidney–293 (HEK 293) cells were 
recorded using the whole-cell patch-clamp technique in response to 
the application of 10 mM Ca2+. For more detailed functional char-
acterization, we chose cis-22a as the most well-studied and repre-
sentative of PCHPDs. At −74-mV membrane potential, this highly 
selective PCHPD antagonist produced potent inhibition of hTRPV6- 
mediated currents with a half-maximal inhibitory concentration (IC50) 
of 82 ± 25 nM (n = 7) (Fig. 1, A and B). The current-voltage (I-V) 
curve (Fig. 1C) showed strong inward rectification, typical for 
TRPV6 channels, and a positive reversal potential (Erev), consistent with 
their high Ca2+ selectivity in the presence and absence of cis-22a. 
Recovery of hTRPV6-mediated currents from cis-22a inhibition was 
slow and reached about 80% of their control amplitude after a 7-min 
washout (fig. S1A). cis-22a inhibited rat TRPV6 (rTRPV6)–mediated 
currents with similar potency to hTRPV6- mediated currents (Fig. 1D 
and fig. S1, B and D).
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Compared to cis-22a, its diastereomer trans-22a (21) showed 
less potent current inhibition at 10 M concentration (fig. S1, E to I). 
We also synthesized Br-cis-22a, a brominated PCHPD analog of 
cis-22a (see Materials and Methods and fig. S2A). The inhibitory 
potency of Br-cis-22a, estimated by measuring the uptake of Cd2+ 
into hTRPV6-expressing HEK 293 cells using the calcium-5 fluo-
rescence reporter FLIPR assay (22) (IC50 = 0.96 ± 0.03 M; n = 12) 
(see Materials and Methods and fig. S2B), was also in submicromo-
lar range, comparable to the inhibitory potency of cis-22a (21, 23). 
Consistently, electrophysiological recordings showed similar extents 
of hTRPV6 current inhibition by Br-cis-22a and cis-22a at 0.1 and 
10 M concentrations (Fig. 1E and fig. S2, C to E). Our functional 
experiments, therefore, demonstrated that cis-22a and its bromi-
nated analog Br-cis-22a are potent TRPV6 inhibitors.
Inhibitor-bound crystal structure of rTRPV6
To investigate the molecular mechanism of TRPV6 inhibition by 
PCHPDs, we decided to use x-ray crystallography first. Of several 
previously developed TRPV6 constructs (26–29), we chose rTRPV6 
construct TRPV6* (see Materials and Methods) that produces well- 
diffracting crystals and yields structures with the physiologically 
relevant swapped arrangement of the TM domains (27). TRPV6* 
displays functional behavior similar to wild type but shows no ap-
parent inactivation by CaM because we truncated the C terminus 
that contains a binding site of CaM (27, 30). As a cocrystallization 
PCHPD partner of TRPV6*, we chose Br-cis-22a (Fig. 2A), the 
heavy bromine atom of which anomalously scatters x-rays. Crystals 
of TRPV6* grown in the presence of Br-cis-22a belonged to the 
P4212 space group and diffracted to 3.7 Å resolution. We solved the 
structure of the TRPV6*–Br-cis-22a complex by molecular replace-
ment and built a model that was refined to good crystallographic 
statistics and stereochemistry (table S1).
The structure of TRPV6*–Br-cis-22a has an architecture typical 
for the vanilloid subfamily TRP channels. It is composed of (i) a 
pore-forming TM domain, which includes six TM helices (S1 to S6) 
and a pore loop (P-loop) between S5 and S6, and (ii) a large intra-
cellular skirt domain with the walls mainly built of ankyrin repeat 
domains, enclosing a ~50 × 50 Å wide cavity underneath the ion 
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Fig. 1. Functional characterization of TRPV6 inhibition by PCHPDs. (A) Representative whole-cell currents recorded from HEK 293 cells expressing hTRPV6 and nor-
malized to their maximal value. Throughout the experiment, 10 mM Ca2+ solution was exchanged to the same solution containing the consecutively added dimethyl 
sulfoxide (DMSO), increasing concentrations of cis-22a (0.01 to 3 M), and followed by La3+, as indicated by the gray bars. The arrows show time points when cis-22a was 
added. (B) Dose-response curve for hTRPV6 inhibition by cis-22a with calculated IC50 (means ± SEM; Hill coefficient, 1.25; n = 7). The inhibition was calculated relative to 
the current in DMSO. (C) Representative I-V curves before (DMSO) and after addition of cis-22a (0.1 and 3 M). (D) Inhibition of hTRPV6- and rTRPV6-mediated currents 
(means ± SEM and individual values) by 0.1 M cis-22a. (E) Inhibition of hTRPV6-mediated current (means ± SEM and individual values) by cis-22a and Br-cis-22a at 0.1 M 
concentration.
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channel (Fig. 2, B and C). Diffraction data collected at 0.92-Å wave-
length revealed three types of strong (>4) peaks in the anomalous 
difference Fourier map. The first peak coincides with the main cat-
ion binding site at the extracellular entrance to the ion channel se-
lectivity filter formed by the side chains of D541. Since no density of 
Br-cis-22a shape was observed close to this peak, it likely represents 
either free residual bromine in the Br-cis-22a sample or a calcium 
ion that has a small but measurable scattering at 0.92 Å wavelength 
( f ″, ~0.5 e). Confirming the lack of Br-cis-22a binding at this loca-
tion, attempts to introduce the Br-cis-22a molecule here resulted in 
strong negative peaks in the Fo − Fc difference map.
The second peak is in close proximity to the lipid-binding site 2 
(LBS-2), which was identified in the previous cryo-EM structures of 
TRPV6 (29, 31). LBS-2 is located in the intracellular half of the lipid 
membrane bilayer, right above the S4-S5 linker, at the interface be-
tween S3, S4, and S4-S5 linker of one subunit and S5 and S6 of the 
neighboring subunit (Fig. 2D). There is a sausage-like density right 
next to the second peak that has never been observed in crystal struc-
tures of rTRPV6 before (26, 27, 29). The size and shape of this density 
suggest a possibility that the LBS-2 is also a binding site for Br-cis-22a, 
mainly formed by hydrophobic side chains. The third peak in the 
anomalous difference Fourier map is located at the ion channel intra-
cellular entrance (Fig. 2E). Right next to this peak is a robust density 
that fits the molecule of Br-cis-22a. Therefore, the ion channel intra-
cellular entrance appears as the second type of binding site where Br-
cis-22a acts as a blocker that plugs the pore and physically obstructs 
ion conductance. To verify the two types of putative PCHPD binding 
sites identified crystallographically, we applied cryo-EM to hTRPV6.
Cryo-EM structures of hTRPV6
In the crystal structure of TRPV6*–Br-cis-22a, binding of Br-cis-22a 
at the ion channel intracellular entrance (Fig. 2E) occurs at a similar 
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Fig. 2. Crystal structure of inhibitor-bound rTRPV6. (A) Chemical structure of the inhibitor Br-cis-22a, with the bromine atom highlighted. (B and C) Side (B) and bottom 
(C) views of the rTRPV6 tetramer, with each subunit shown in different color. Molecules of Br-cis-22a are shown in yellow. Mesh shows omit (2.5, blue) and anomalous 
difference (3.0, pink) electron density. Boxed are regions expanded in (D) and (E). (D and E) Close-up views of the lipid-binding site 2 (LBS-2) (D) and the pore binding site 
(E). Only two of four TRPV6 subunits are shown in (E), with the front and back subunits removed for clarity.
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location where the CaM lysine K115 side chain blocks the TRPV6 
pore during Ca2+-induced inactivation (30). It appears that endoge-
nous CaM copurifies with full-length hTRPV6 (hTRPV6-FL) in most 
of our protein preparations, similar to its copurification with the 
full-length rTRPV6 that resulted in the rTRPV6-CaM complex 
structure (30). To avoid possible structural interference between the 
binding of inhibitors and CaM, we truncated the CaM binding site–
containing C terminus of hTRPV6, similar to the crystallizing construct 
TRPV6* (see Materials and Methods). For the resulting construct 
hTRPV6-CtD, we solved the apo state structure by cryo-EM (Fig. 3A, 
figs. S3 and S4, and table S2) and found it nearly identical to the 
previously published apo state structure of hTRPV6-FL (fig. S5) 
(31), with no signs of CaM in the skirt-enclosed cavity underneath 
the ion channel. We therefore used hTRPV6-CtD to visualize mo-
lecular interactions of hTRPV6 with PCHPD inhibitors.
The cryo-EM structure of hTRPV6-CtD solved in the presence of 
cis-22a (Fig. 3, B and C) revealed two types of nonprotein densities 
in the TM domain that appear different from densities in the apo 
state structure (Fig. 3A). They are located at the same two sites (Fig. 3, 
H and M) that were identified as the putative Br-cis-22a binding 
sites in the crystal structure of TRPV6*–Br-cis-22a (Fig. 2, D and E). 
The presence of the central pore site (Fig. 3M) is unambiguous be-
cause the density at this site is not present in the apo state structure 
(Fig. 3A) but observed for all PCHPDs in the corresponding cryo-
EM structures (Fig. 3, M to Q). For cryo-EM structures, we did not 
have the advantage of using anomalous signals to orient the inhibi-
tors at their putative binding sites, as we had for the TRPV6*–Br-
cis-22a crystal structure (Fig. 2E). However, given the similarity of 
PCHPD chemical structures, the same procedures of protein ex-
pression and purification for crystallographic and cryo-EM experi-
ments, 100% amino acid sequence identity, and similarity in pore 
geometry between rat and human TRPV6, we kept the orientation 
of PCHPDs at the central pore site in cryo-EM structures the same 
as the orientation of Br-cis-22a in the crystal structure.
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Fig. 3. Cryo-EM structures of hTRPV6 in the absence and presence of different PCHPD inhibitors. (A and B) Side and bottom views of cryo-EM density for hTRPV6 in 
the absence of inhibitors (A) and in the presence of cis-22a (B), with each subunit shown in a different color and the inhibitor shown in red. Boxed regions in (B) are expanded 
in (H) and (M). (C to G) Chemical structures of different PCHPD inhibitors. (H to Q) Close-up views of the inhibitor-bound LBS-2 (H to L) and the inhibitor-bound pore 
binding site (M to Q). In (M) to (Q), only two of four TRPV6 subunits are shown, with the front and back subunits removed for clarity. Red mesh shows densities for different 
PCHPD inhibitors.
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The other putative cis-22a binding site identified by cryo-EM 
(Fig. 3H) overlaps with LBS-2, which is likely occupied by a choles-
terol lipid in natural conditions. In the apo state structure, the LBS-2 
density matches the shape of cholesteryl hemisuccinate (CHS), 
which was present in our experimental buffers (see Materials and 
Methods and Fig. 4, A and C). The LBS-2 density in the presence of 
cis-22a is shorter and matches the size and shape of the inhibitor 
(Fig. 4, B and D). Similar densities were also observed for other 
PCHPD inhibitors (Fig. 3, I to L). Given different appearances of 
LBS-2 cryo-EM density in the inhibitor-free and inhibitor-bound 
structures (Fig. 4) as well as clear signals in the crystallographic 
anomalous and omit maps of TRPV6* (Fig. 2), our data strongly 
support the binding of PCHPD inhibitors at the LBS-2. However, 
we cannot exclude a possibility that occupancy of the LBS-2 by 
PCHPDs is partial, as they likely compete for binding with the sur-
rounding membrane lipids.
MD simulations of the LBS-2 and the pore binding site
To further verify both LBS-2 and the pore binding site identified by 
structural methods, we ran molecular dynamics (MD) simulations 
(see Materials and Methods). The 25-ns MD simulations of cis-22a 
bound to either the LBS-2 in each monomer of the hTRPV6-CtD 
tetramer or to the pore binding site indicated a moderate flexibility 
of the compound within the pockets. Compared to the initial, iden-
tical poses of cis-22a bound to LBS-2 in each of the four monomers 
of the hTRPV6-CtD tetramer determined by the cryo-EM structure, 
poses obtained during the MD simulations changed very little (fig. 
S6, A and B). The average root mean square deviations (RMSDs) for 
cis-22a at the LBS-2 sites were 1.5 to 2.0 Å, whereas the RMSD for 
the pore-bound compound was 1.6 Å (fig. S6, D and E). The over-
all conformation of the protein was stable with respect to the final 
energy-minimized structure. For both simulations, the average C 
RMSD values for the whole protein and TM helices were 3.7 and 2.0 Å, 
respectively (fig. S6, C and F). To understand whether cis-22a 
forms a stable interaction with the surrounding residues during the 
MD simulations, we calculated the average minimum distances be-
tween heavy atoms in the residue side chains and cis-22a (table S3). 
For LBS-2, the minimum distances for residues L460, M466, and 
Q483 remained below the cutoff (4.0 Å) during the entire MD sim-
ulation for all bound cis-22a molecules. Among these, Q483 is the key 
residue for lipid recognition in TRPV6 (29, 31). It is located in a sim-
ilar position to E570 in TRPV1 (32), an important residue involved 
in lipid and ligand binding (32). The pore binding site is composed 
of a fewer number of residues compared to LBS-2, but each one of 
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Fig. 4. Nonprotein densities surrounding the TM domain of TRPV6. (A and B) Side views of cryo-EM density for the TM domain of hTRPV6 in the absence of inhibitors 
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four TRPV6 subunits contributes the same set of symmetrically ar-
ranged residues. The simulation run highlighted the stability of the 
complex formed between cis-22a and the central ion channel pore, 
with minimum distances below 3.0 Å for all analyzed residues. Our 
MD simulations, therefore, strongly support the two types of PCHPD 
binding sites in TRPV6 identified by structural methods.
Functional evaluation of the PCHPD pore binding site
To assess the role of the pore site in TRPV6 inhibition by PCHPDs, 
we mutated the pore-lining residues in close proximity to this site 
(Fig. 5A) and tested the inhibition of the mutated channels by cis-
22a using the FLIPR assay (fig. S7A). HEK 293 cells expressing 
I575A and D580N mutants showed robust hTRPV6-mediated Cd2+ 
influx, while those transfected with G579A, D580A, D580K, W583A, 
and R584A mutants showed no detectable Cd2+ influx (fig. S7B). The 
cells transfected with G579A mutant channels showed basal Ca2+ 
levels typical for wild type, while for I575A, D580A/K, W583A, and 
R584A mutants, the basal Ca2+ levels were higher. The fivefold and two-
fold lower Cd2+ influx through hTRPV6 mutants I575A and D580N, 
respectively, was resistant to inhibition by 0.25 M cis-22a, which 
blocked 70% of the wild-type hTRPV6- mediated Cd2+ entry (Fig. 5B 
and fig. S7B). Increasing the concentration of cis-22a to 1 M re-
sulted in the nearly complete block of Cd2+ influx through the wild-
type channel but still failed to inhibit Cd2+ influx through I575A 
and D580N mutant channels (fig. S7C). We also tested the effect on 
Cd2+ influx of the recently synthesized PCHPDs inhibitor 3OG, 
which is among the most promising inhibitors in this class (23). We 
found that 1 M 3OG showed no inhibition of Cd2+ influx through 
D580N mutant channels, while it inhibited nearly 70% of Cd2+ 
influx through wild-type hTRPV6 channels (fig. S7D). The same 
concentration of 3OG produced ~15% inhibition of Cd2+ entry 
through I575A mutant channels.
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cis-22a was added. (F) Dose-response curves with calculated IC50 for wild-type (means  ± SEM; Hill coefficient, 1.25; n = 7) and W583F mutant (means ± SEM; Hill coefficient, 
1.5; n = 7) hTRPV6 channels.
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The impact of mutations I575A, D580N, D580K, and W583F at 
the pore site on hTRPV6 inhibition by PCHPDs was also character-
ized in electrophysiological experiments by comparing the reduction 
of currents in response to cis-22a at 0.1 and 10 M concentrations 
(Fig. 5, C and D). For wild-type hTRPV6, the application of 0.1 and 
10 M cis-22a resulted in a significant reduction of currents by 
57.5 ± 4.6% and 97.2 ± 0.7%, respectively. In contrast, currents 
through the D580K pore mutant channels were not significantly 
affected by applications of either 0.1 or 10 M cis-22a. The pore 
mutant W583F, which had shown measurable inhibition of currents 
by cis-22a, was further chosen for the detailed comparison with 
wild-type hTRPV6. Currents through the W583F channels were 
not significantly altered by 0.1 M cis-22a but showed a 79.1 ± 1.7% 
reduction in response to 10 M cis-22a application. The I-V curve 
for W583F (fig. S7I) displayed a positive Erev, in line with unaltered 
calcium selectivity of the mutant channel. The cis-22a dose-response 
curve for W583F yielded an IC50 value of 6.19 ± 0.67 M (n = 7), 
indicative of a 75-fold lower affinity of cis-22a to W583F compared 
to wild-type channels (Fig. 5, E and F, and fig. S7, F and G). This 
dramatic reduction in cis-22a affinity is likely underestimated, as 
the correction for the slow reactivation of currents at high concen-
trations of cis-22a (Fig. 5E) would increase the IC50 value for W583F 
even more. Therefore, the strong functional effects of mutations at 
the intracellular pore entrance corroborated the importance of the 
structurally resolved pore site for TRPV6 inhibition by PCHPDs.
Functional evaluation of the LBS-2
To address the role of LBS-2 in TRPV6 inhibition by PCHPDs, we 
mutated several residues in close proximity to this site (Fig. 6A). Those 
hTRPV6 mutants that mediated an easily measurable Cd2+ influx 
(20% or higher compared to wild-type channels) were analyzed for 
inhibition by cis-22a (fig. S7E). In response to the application of 
0.25 M cis-22a, the R470A mutant showed a fivefold reduction in 
the Cd2+ influx inhibition by cis-22a compared to the wild-type 
channel, whereas for R470K, the reduction was only modest (Fig. 6B). 
Both Q483A and Q483K mutants showed more than 1.5-fold re-
duced inhibition of the Cd2+ influx by 0.25 M cis-22a compared to 
wild-type channels. In addition, a modest but significant reduction 
in Cd2+ influx inhibition by 0.25 M cis-22a was observed for 
C463T and N464S mutants of hTRPV6 compared to the wild-type 
channel.
Four LBS-2 mutants, N464L, R470A, Q483A, and F504Y, were 
further analyzed electrophysiologically. In response to the applica-
tion of 0.1 M cis-22a, all these mutants showed significantly re-
duced cis-22a inhibition compared to wild type, especially N464L 
and R470A (Fig. 6, C and D). In general, however, the reduction of 
cis-22a inhibition demonstrated by the LBS-2 mutants was much 
weaker than the one caused by mutations at the pore site. The 
R470A mutation (31) was analyzed in more detail. The I-V curve for 
R470A displayed a typical TRPV6 inward current rectification (fig. 
S7H), while the cis-22a dose-response curve yielded the IC50 value 
of 0.50 ± 0.11 M, indicating a sixfold lower affinity of the R470A 
mutant channels to cis-22a compared to wild-type hTRPV6 (Fig. 6, 
E and F, and fig. S7, F and G).
The strong effects of mutations at the pore intracellular entrance 
(I575, D580, and W583) on PCHPD inhibition suggest that the pore 
site is the main PCHPD binding site that mediates TRPV6 channel 
block. PCHPD binding to the LBS-2 may play an important role in 
allosteric modulation of the pore binding site, thereby participating 
in inhibition of the channel function. To further study the role of 
the two binding sites in TRPV6 inhibition by PCHPDs, we made a 
double mutant, consisting of the R470A mutation at the LBS-2 and 
the W583F mutation at the pore site (fig. S8A). In response to the 
application of 10 M cis-22a (fig. S8, B and C), the double mutant 
showed much weaker inhibition of currents compared to the single 
mutants, indicating that the cumulative effect of R470A and W583F 
mutations on blocking efficiency is stronger than additive. Thus, 
the LBS-2 mutations might indirectly affect cis-22 affinity, probably 
due to the allosteric modulation of the pore binding site. In conclu-
sion, we propose that the pore site is the main PCHPD binding site 
where the inhibitor plugs the channel and, hence, blocks the ion 
conductivity.
Inhibitor-induced conformational changes in the ion 
channel pore
To understand the molecular mechanism of inhibition, we com-
pared the inhibitor-free and inhibitor-bound structures of TRPV6. 
The overall shape of the channel does not undergo substantial 
changes upon inhibitor binding (Fig. 3, A and B). However, the ion 
channel pore shows different conformations in the presence and 
absence of cis-22a (Fig. 7, A and B). In the apo state (fig. 7A), the 
calculated pore radius suggests that the lower gate region is wide 
open for conducting hydrated ions. The pore’s most narrow con-
striction at the gate region is defined by the side chains of I575 (9.9 Å), 
which constrict the pore to a similar extent as the residues that form 
the narrowest pore constriction at the intracellular gate region of 
open TRPV1 (33) (interatomic distance of 9.3 Å, measured between 
the side chains of I679) and TRPV3 (34, 35) (interatomic distance of 
8.7 to 9.7 Å, measured between the side chains of I674). The pore- 
lining S6 segments, which are entirely -helical in the closed state, 
show a local -helical–to–-helical transition associated with chan-
nel opening (31). In the presence of cis-22a, the -to- transition in 
S6 remains intact, but the pore becomes markedly narrower as the 
lower portions of S6 helices are pulled back toward the center of the 
pore, likely attracted by the inhibitor wedged in the middle (Fig. 7B). 
The pore’s narrow constriction at the gate region is still defined by 
the side chains of I575, but its smaller size (5.8 Å) suggests the for-
mation of a hydrophobic seal impermeable for ions. This hydro-
phobic seal is not necessary to prevent ion conduction through the 
pore, as it is already blocked by cis-22a (Fig. 3M), but it may be 
important to energetically stabilize the inhibited state.
Inactivation-mimicking mechanism of TRPV6 inhibition  
by PCHPDs
The PCHPD-induced conformational changes in the TRPV6 pore 
(Fig. 7, A and B) are very different from the expected conversion of the 
open channel to its closed state, which is characterized by -helical 
S6 and a distinct pore profile (Fig. 7C) (31), as previously observed 
for the inhibitor 2-APB (29). Instead, the PCHPD-induced confor-
mational changes are similar to those observed in TRPV6 structures 
inactivated by CaM (30). The side chain of CaM residue K115 in the 
TRPV6-CaM complex (Fig. 7D) plugs the ion channel intracellular 
entrance in a similar way to cis-22a (Fig. 7E). Superposition of the two 
structures (Fig. 7F) clearly shows that the different stimuli result in 
nearly identical conformations of the lower pore of TRPV6. Trypto-
phan W583, which is highly conserved across TRPV5 and TRPV6 
channels (30), plays a central role in K115 binding and CaM inacti-
vation. Four of these tryptophan residues, one from each subunit of 
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TRPV6, form a tight cubic cage with 4.2 Å between the plane of 
each indole ring and the -amino group of K115. This tryptophan 
cage provides a unique environment for an atypically strong cation- 
interaction between the -system of four tryptophan indole rings 
and the positively charged -amino group of lysine. The importance 
of W583 for CaM-dependent Ca2+-induced inactivation has been 
demonstrated in experiments with TRPV5, where the W583A mu-
tation has resulted in cell death due to increased calcium influx (36). 
Mutations of W583 to leucine and alanine greatly reduced CaM- 
mediated inactivation of TRPV5 and converted the channel into the 
open state (37, 38). Tryptophan W583 seems to also be crucial for 
TRPV6 inhibition by PCHPDs as the W583F mutation resulted in 
significant reduction of cis-22a inhibition (Fig. 5, C to F).
The W583F mutation also alters the inactivation behavior of 
TRPV6 (fig. S9). Wild-type TRPV6 exhibits inactivation visible as a 
time-dependent decrease in the current amplitude to about 50 to 
70% of its maximum value over the first ~180 s of the electrophysi-
ological experiment (fig. S9, B and E). This inactivation is calcium 
dependent, as it is eliminated upon replacement of the 10 mM 
Ca2+-containing solution with the divalent-free sodium-containing 
solution (DVF) (fig. S8, D to F). However, the type of the current 
carrier, sodium or calcium, does not seem to be important for 
TRPV6 inhibition by PCHPD since the IC50 for cis-22a–induced 
inhibition of sodium currents (0.178 ± 0.067 M) is not significantly 
different from calcium currents (fig. S8, G and H). In contrast, the 
degree of calcium-dependent inactivation is strongly affected by 
mutations that alter PCHPD inhibition. Among all these mutations, 
the reduction of inactivation caused by W583F is relatively moder-
ate (fig. S9, A to C). This is likely due to the phenol rings of phenyl-
alanine W583F, which, similar to indole rings of tryptophans W583, 
are capable of creating a -system that can form a cation- inter-
action with the positively charged -amino group of lysine K115 
(Fig.  7D). Other mutations, which weakened PCHPD inhibition, 
exhibited a stronger reduction of inactivation, independent of whether 
they were introduced at the pore site (fig. S9, A to C) or LBS-2 (fig. 
S9, D to F). At the same time, all these mutants had current ampli-
tudes and I-V curves comparable to wild-type channels (fig. S10 
and Fig. 1C). Our results therefore suggest that any alterations in 
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Fig. 6. Functional analysis of the LBS-2. (A) Schematic view of the LBS-2 in hTRPV6 bound to cis-22a (yellow), with the surrounding residues shown as sticks. (B) Average 
percentage inhibition of Cd2+ entry into HEK 293 cells transiently expressing wild type hTRPV6 and LBS-2 mutants in response to 10-min application of 0.25 M cis-22a, 
measured using the FLIPR assay (n ≥ 6 except for L460F where n = 3; means ± SD). Statistically significant difference in inhibition of the mutant compared to the wild-type 
channels is indicated by “*” (P < 0.001). (C) Averaged amplitude of whole-cell currents (means ± SEM) recorded from HEK 293 cells expressing wild-type hTRPV6  and mutant 
channels N464L, R470A, Q483A, and F504Y, normalized to the current amplitude in DMSO (before application of cis-22a). Throughout the experiment, 10 mM Ca2+ 
solution was exchanged to the same solution containing the consecutively added DMSO, cis-22a (0.1 and 10 M), and followed by Ca2 +–free solution containing  La3+, as 
indicated by the gray bars. (D) Percent inhibition of wild-type and mutant hTRPV6-mediated currents (means ± SEM and individual values) by 0.1 (left) and 10 (right) M 
cis-22a. (E) Representative whole-cell currents recorded from HEK 293 cells expressing R470A mutant and normalized to the current amplitude in DMSO. Throughout the 
experiment, 10 mM Ca2+ solution was exchanged to the same solution containing the consecutively added DMSO, increasing concentration of cis-22a (0.03 to 10 M), 
and followed by La3+, as indicated by the gray bars. The arrows show time points when cis-22a was added. (F) Dose-response curves for wild-type and R470A mutant 
hTRPV6 channels fitted by the logistic equation (means ± SEM; Hill coefficient, 1.25 and 0.98 for wild type and R470A, respectively).
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the pore geometry, whether they are caused by direct changes in the 
pore composition or via allosteric modulation, affect both the PCH-
PD inhibition and calcium-dependent inactivation and emphasize 
the common molecular origin of the two processes.
A number of recently reported x-ray and cryo-EM structures of 
TRP channels provide insights into the mechanisms of their perme-
ation and modulation by endogenous ligands, natural products, 
and drug-like small molecules (table S4) (39). Most inhibition and 
activation mechanisms reported to date involve a displacement of 
endogenous ligands (e.g., ATP and lipids) (31) from their respective 
binding sites, leading to stabilization of either the open (activation) 
or closed (inhibition) states of the channel (32, 40). In particular, a 
number of small-molecule inhibitors (e.g., cannabidiol, capsazepine, 
and econazole) (32, 41, 42) displace the endogenous activating 
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lipids (29, 42) from the S4-S5 pocket. In this regard, the high-affinity 
inactivation-mimicking TRPV6 inhibition by PCHPDs has no prec-
edent among TRP channels. It is also unique for ion channels over-
all because the structural mechanism of inactivation by CaM has 
so far been characterized for TRPV6 and TRPV5 channels only 
(30, 37, 38). By using this mechanism of the evolutionary optimized 
physiological function of inactivation, the usage of PCPHD inhibi-
tors as drugs might be less invasive, more compatible with natural 
processes, and, therefore, more effective and bear less adverse side 
effects.
In conclusion, PCHPDs are potent and selective TRPV6 chan-
nel inhibitors that act as inactivation-mimicking pore blockers. 
Further expansion of this class of biomimetic inhibitors and their 
in vivo examination will help to proceed with the development of 
therapeutic substances targeting TRPV6 and possibly other ion 
channels.
MATERIALS AND METHODS
Synthesis of PCHPDs
cis-22a, 30, 31, and 3OG were synthesized as described previously 
(21). Br-cis-22a was synthesized for x-ray crystallography purposes 
according to the following procedure (fig. S2A). Briefly, the 1-bromo- 
3-methylbenzene (1) was coupled to 1,4-cyclohexanedione mono-
ethylene acetal (2) via Grignard reaction to form the tertiary alcohol 
(3), followed by a multistep procedure to form the required inter-
mediate 4-(m-tolyl)cyclohexan-1-one (4). Then, 4 was subjected to 
reductive amination with 1-(5-bromopyridin-3-yl)piperazine (5) to 
achieve compound Br-cis-22a, which was isolated by column chro-
matography. After characterization, the freebase was converted into 
its respective dihydrochloride salt. All commercial reagents were 
used without further purification. Dry solvents were obtained di-
rectly from a drying solvent system. Chromatographic purifications 
were performed using silica gel (Sigma-Aldrich; 230 to 400 mesh). 
Automated chromatographic purification was performed with 
puriFlash 430 system (Interchim) using Teledyne ISCO normal- 
phase RediSepRf cartridge and detection by ultraviolet absorption 
(214 nm). Low-resolution mass spectra were obtained by electron 
spray ionization (ESI), positive mode (Thermo Scientific LCQ Fleet). 
High-resolution mass spectra were obtained by ESI, positive mode 
(Thermo Scientific LTQ Orbitrap XL). 1H- and 13C-NMR (nuclear 
magnetic resonance) spectra were recorded at 300 and 75 MHz, re-
spectively (Bruker AV300). 1H and 13C chemical shifts are quoted 
relative to solvent signals. MestreNova was used for further analysis 
of the spectra. The purity of the final compound was >95%, as con-
firmed by analytical reversed-phase ultrahigh-performance liquid 
chromatography (RP-UHPLC) with detection at 214 nm, on a 
Dionex UltiMate 3000 RSLC System (DAD-3000 RS Photodiode 
Array Detector) and Dionex Acclaim RSLC 120 column (C18; 3.0 × 
50 mm; particle size of 2.2 m; 120 Å pore size) at a flow rate of 
1.2 ml/min. Data recording and processing were done with Dionex 
Chromeleon Management System (version 6.8) and Xcalibur (ver-
sion 2.2, Thermo Scientific). Eluents for analytical RP-UHPLC were 
as follows: A, milli-Q deionized water with 0.05% trifluoroacetic 
acid (TFA); D, HPLC-grade acetonitrile/milli-Q deionized water 
(9:1) with 0.05% TFA. Conditions for analytical RP-UHPLC were as 
follows: in 4.5 min from 100% A to 100% D and then maintained on 
100% D or in 7.5 min from 100% A to 100% D and then maintained on 
100% D. Chemical names were generated using ChemDraw Profes-
sional 17.0 (PerkinElmer Informatics). The steps of chemical syn-
thesis are described in more detail below.
Procedure for the synthesis of 8-(m-tolyl)-1,4-dioxaspiro[4.5]
decan-8-ol (3)
A solution of 1-bromo-3-methylbenzene (1; 1.2 ml, 1.2 eq) in dry 
tetrahydrofuran (THF) (1 ml) was added dropwise to magnesium 
turnings (342.2 mg, 1.4 eq) in dry THF (1.4 ml) at room tempera-
ture (r.t.) under argon atmosphere. The solution was then heated to 
reflux for 30 min until the complete formation of the Grignard re-
agent. After cooling to r.t., a solution of 1,4-cyclohexanedione mono-
ethylene acetal (2; 1.6 g, 1 eq) in dry THF (2.4 ml) was added to the 
reaction mixture, and the solution was heated again to reflux for 
30 min. After cooling to r.t., the reaction was quenched by the addi-
tion of an aqueous saturated solution of NH4Cl (6 ml) and was ex-
tracted with Et2O (3 × 50 ml). The combined organic phase was dried 
over MgSO4 and evaporated under vacuum. The obtained residue 
was column-chromatographed (hexanes:EtOAc, 95:05 to 75:25) to 
yield 3 as white solids (2.3 g; 93%).
Procedure for the synthesis of 4-(m-tolyl)cyclohexan-1-one (4)
TsOH (177 mg, 0.1 eq) was added to a solution of 3 (9.3 mmol, 1 eq) 
in dry toluene (44 ml) under argon atmosphere, and this solution 
was heated to reflux for 4 hours. The reaction mixture was cooled to 
r.t. and washed with an aqueous saturated solution of NaHCO3 (3 × 
50 ml). The organic phase was dried over MgSO4 and evaporated 
under vacuum. The obtained oil was used in the next step without 
further purification. A solution of the previously obtained com-
pound in EtOAc (20 ml) and 10% Pd/C (229 mg, 0.3 eq) was hydro-
genated for 16 hours at r.t. and atmospheric pressure. The reaction 
mixture was filtered over a pad of Celite (washed thoroughly 3 × 
50 ml with EtOAc) to remove the catalyst. The solvent was removed 
under vacuum, and the crude was used in the next step without fur-
ther purification (colorless oil). The previously obtained compound 
was solubilized in a mixture of acetone:water (1:1; 40 ml). To this 
solution, pyridinium p-toluenosulfonate (4.6 g, 2 eq) was added and 
the mixture was stirred at 60°C for 6 hours. After cooling to r.t., the 
organic solvent was removed under vacuum and the resulting aque-
ous phase was extracted with EtOAc (3 × 50 ml). The collected or-
ganic phase was dried over Na2SO4 and evaporated. The crude was 
column-chromatographed (hexanes:EtOAc, 9:1) to yield 4 as a 
colorless oil (1.1 g; 63%). 1H-NMR (CDCl3):  7.25 to 7.19 (m, 1H), 7.05 
(d, J = 7.5 Hz, 3H), 2.99 (tt, J = 12.1, 3.4 Hz, 1H), 2.58 to 2.48 (m, 4H), 
2.36 (s, 3H), 2.25 to 2.18 (m, 2H), 2.02 to 1.87 (m, 2H). 13C-NMR 
(CDCl3):  211.4, 144.9, 138.3, 128.6, 127.6, 127.4, 123.8, 42.9, 41.5, 34.1, 
21.6. HRMS (high-resolution mass spectrometry) mass/charge ratio 
(m/z) calculated for C13H16O: 188.1201 ([M]+); found: 211.1091 ([M + Na]+).
Procedure for the synthesis of 1-(5-bromopyridin-3-yl)-4-((1s,4s)- 
4-(m-tolyl)cyclohexyl)piperazine, double hydrochloride  
salt (Br-cis-22a)
A solution of 4 (94.2 mg, 1 eq) in DCE (1,2-dichloroethane) (5 ml) 
was added to 1-(5- bromopyridin-3-yl)piperazine (5; 145.3 mg, 1.2 eq), 
AcOH (29 l, 1.0 eq), and NaBH(OAc)3 (127.2 mg, 1.2 eq). The solu-
tion was then stirred at r.t. for 48 hours. After completion, moni-
tored by thin- layer chromatography, the organic phase was evaporated 
and the crude was column-chromatographed (hexanes:EtOAc, 
90:10 + 0.5% Et3N). Last, Br-cis-22a was solubilized in Et2O and pre-
cipitated by addition of a methanol solution of HCl as white powder 
(99 mg; 41%, white solids). 1H-NMR (CD3OD):  8.42 (d, J = 2.6 Hz, 1H), 
8.30 (d, J = 1.6 Hz, 1H), 8.06 (t, J = 2.1 Hz, 1H), 7.23 to 7.19 (m, 3H), 7.01 
(t, J = 3.7 Hz, 1H), 4.07 (d, J = 13.6 Hz, 2H), 3.77 (d, J = 11.9 Hz, 2H), 
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3.47 (dd, J = 12.3, 9.7 Hz, 3H), 3.26 (d, J = 11.3 Hz, 2H), 2.96 (t, J = 
6.7 Hz, 1H), 2.36 to 2.28 (m, 5H), 2.10 to 1.85 (m, 6H). 13C-NMR (CD3OD): 
 149.0, 144.8, 139.2, 136.3, 131.6, 131.2, 129.5, 129.0, 127.8, 125.3, 
123.2, 66.3, 49.8, 45.5, 39.2, 29.1, 24.9, 21.6. HRMS m/z calculated for 
C22H29BrN3: 414.1539 ([M + H]+); found: 414.1555.
X-ray crystallography and Cryo-EM
Constructs
The hTRPV6-FL (residues 1 to 725) used for cryo-EM was cloned 
into a pEG BacMam vector (43), with a C-terminal thrombin cleavage 
site (LVPRG), followed by a streptavidin affinity tag (WSHPQFEK). 
hTRPV6-CtD (residues 1 to 666) was produced from the hTRPV6-
FL construct using standard molecular biology procedures. The 
TRPV6* construct used for crystallization was similarly made by 
introducing rTRPV6 into the BacMam vector (27). Compared to 
wild-type rTRPV6, TRPV6* is C-terminally truncated by 59 resi-
dues and contains three point mutations in the ankyrin repeat do-
main (I62Y, L92N, and M96Q).
Expression and purification
TRPV6* and hTRPV6-CtD constructs were expressed and purified 
as previously described for TRPV6* (27) and wild-type hTRPV6 
(31) with slight modification. Bacmids and baculoviruses were pro-
duced using a standard method (43). In short, baculovirus was 
made in Sf9 cells for ~72 hours (Thermo Fisher Scientific, myco-
plasma test negative, GIBCO no. 12659017) and was added to the 
suspension-adapted HEK 293 cells lacking N-acetyl-glucosaminyl-
transferase I (mycoplasma test negative, ATCC no. CRL-3022) that 
was maintained in FreeStyle 293 media (Gibco-Life Technologies 
no. 12338-018) supplemented with 2% fetal bovine serum (FBS) at 
37°C and 5% CO2. Ten to 24 hours after transduction, 10 mM sodium 
butyrate was added to enhance protein expression, and the tem-
perature was reduced to 30°C. At 48 to 72 hours after transduction, 
the cells were harvested by centrifugation at 5471g for 15 min using 
a Sorvall Evolution RC centrifuge (Thermo Fisher Scientific), washed 
in phosphate-buffered saline (pH 8.0), and pelleted by centrifuga-
tion at 3202g for 10 min using an Eppendorf 5810 centrifuge. The 
cell pellet was resuspended in ice-cold lysis buffer, containing 20 mM 
tris-Cl (pH 8.0), 150 mM NaCl, 0.8 M aprotinin, 4.3 M leupeptin, 
2 M pepstatin A, 1 mM phenylmethylsulfonyl fluoride, and 1 mM 
-mercaptoethanol (ME). Cells were subsequently lysed using a 
Misonix Sonicator with a preset program (6 cycles of 15 s “on” at 
the amplitude of 8 followed by 15 s “off”; this program was repeated 
three times for optimal cell lysis) under constant stirring on ice. Un-
broken cells and cell debris were pelleted in an Eppendorf 5810 cen-
trifuge at 3202g and 4°C for 10 min. The supernatant was subjected 
to ultracentrifugation in a Beckman Coulter ultracentrifuge using a 
Beckman Coulter Type 45 Ti rotor at 186,000g and 4°C for 1 hour 
to pellet the membranes. The membrane pellet was mechanically 
homogenized and solubilized in the lysis buffer supplemented with 
1% (w/v) n-dodecyl -d-maltoside (DDM) and 0.1% (w/v) CHS un-
der stirring at 4°C for 2 hours. Insoluble material was removed by 
ultracentrifugation for 1 hour in a Beckman Coulter Type 45 Ti 
rotor at 186,000g, and the supernatant was added to strep resin and 
rotated for 14 to 16 hours at 4°C. Next, the resin was washed with 
10 column volumes of wash buffer containing 20 mM tris-HCl 
(pH 8.0), 150 mM NaCl, 1 mM ME, 0.01% (w/v) glyco-diosgenin 
(GDN), and 0.001% (w/v) CHS, and the protein was eluted with the 
same buffer supplemented with 2.5 mM d-desthiobiotin. The eluted 
protein was concentrated using a 100-kDa NMWL (nominal molec-
ular weight limit) centrifugal filter (MilliporeSigma Amicon) to 0.5 ml 
and then centrifuged in a Sorvall MTX 150 micro-ultracentrifuge 
(Thermo Fisher Scientific) using a S100AT4 rotor for 30 min at 
66,000g and 4°C before injecting into a size exclusion chromatog-
raphy (SEC) column. All constructs were further purified using a 
Superose 6 10/300 GL SEC column attached to an AKTA FPLC (fast 
protein liquid chromatography) (GE Healthcare) and equilibrated 
in 150 mM NaCl, 20 mM tris-HCl (pH 8.0), 1 mM ME, 0.01% GDN, 
and 0.001% CHS. The tetrameric peak fractions were pooled and 
concentrated using a 100-kDa NMWL centrifugal filter (MilliporeSigma 
Amicon) to 2 to 4 mg/ml.
All PCHPD inhibitors were dissolved in dimethyl sulfoxide 
(DMSO) to a concentration of 10 mM. The inhibitor cis-22a was 
further diluted in buffer containing 20 mM tris-HCl (pH 8.0), 150 mM 
NaCl, 1 mM ME, 0.01% GDN, and 0.001% CHS to a concentration 
of 2.5 mM. All PCHPD inhibitors were added to the protein 30 min 
before grid preparation or crystallization at the final concentration 
of 1 mM (Br-cis-22a, 3OG, 30, and 31) or 0.5 mM (cis-22a).
Crystallization and structure determination
Purified TRPV6* protein was concentrated to ~2.5 mg/ml. After the 
addition of 1 mM Br-cis-22a inhibitor (10 mM stock in DMSO), 
the protein was incubated for ~30 min on ice and ultracentrifuged 
(Ti 100 rotor, 86,500g, 40 min, 4°C) to get rid of any aggregated material. 
Crystals of TRPV6* were grown in the hanging drop configuration 
at 20°C in the reservoir solution containing 20 to 24% PEG 350 MME 
(methoxypolyethylene glycol, molecular weight 350), 50 mM NaCl, 
50 mM tris-HCl (pH 8.0 to 8.5), and 10 mM ammonium formate. 
They were cryoprotected by serial transfer into buffers composed of 
100 mM NaCl, 100 mM tris-HCl (pH 8.2), 0.5 mM DDM, 10 mM 
ammonium formate, and increasing concentrations of PEG 350 MME 
with the maximum concentration of 33 to 36% and then flash-frozen 
in liquid nitrogen. X-ray diffraction data collected at The Advanced 
Photon Source (in Argonne, Illinois, USA) (beamline 24-ID-C) were 
indexed, integrated, and scaled using XDS (44). The initial phase 
information was obtained and the TRPV6*–Br-cis-22a structure was 
solved by molecular replacement using Phaser (45), for which the 
structure of TRPV6* (PDB ID: 5WO7) (27) served as a search probe. 
The structure was further improved by alternating cycles of refine-
ment in Phenix (46) and model building in Coot (47).
Cryo-EM sample preparation and data collection
Au/Au grids were prepared as described in the literature (48). Briefly, 
grids were prepared by first coating C-flat (Protochips Inc., Morrisville, 
NC) CF-1.2/1.3-2Au mesh holey carbon grids with ~60 nm of gold 
using an Edwards Auto 306 evaporator. Subsequently, an Ar/O2 
plasma treatment [4 min, 50 W, 35.0 sccm (standard cubic centime-
ters per minute) of Ar, 11.5 sccm of O2] was used to remove the 
carbon with a Gatan Solarus (model 950) advanced plasma cleaning 
system (Gatan, Pleasanton, CA, USA). The grids were again plasma- 
treated (H2/O2, 25 s, 10 W, 6.4 sccm of H2, 27.5 sccm of O2) before 
sample application to make their surfaces hydrophilic. A Mark IV 
Vitrobot (Thermo Fisher Scientific) set to 100% humidity at 4°C was 
used to plunge-freeze the grids in liquid ethane after applying 3 l of 
protein sample to their gold-coated side using a blot time of 3 s, a 
blot force of 3, and a wait time of 20 s. The grids were stored in liq-
uid nitrogen before imaging.
Images of frozen-hydrated particles of hTRPV6 in the absence of 
ligands or presence of cis-22a or 31 were collected on a Titan Krios 
transmission electron microscope (TEM) (Thermo Fisher Scientific) 
operating at 300 kV and equipped with a post-column GIF Quantum 
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energy filter and a Gatan K3 Summit direct electron detection 
(DED) camera (Gatan, Pleasanton, CA, USA) using Leginon (49). 
For hTRPV6 in the presence of cis-22a, 5787 micrographs were col-
lected in counting mode with an image pixel size of 0.83 Å across a 
defocus range of −1.0 to −2.0 m. The total dose of ~58 e− Å−2 was 
attained by using a dose rate of ~16 e− pixel−1 s−1 across 50 frames 
for a 2.5-s total exposure time. For hTRPV6 in the presence of 31, 
6270 micrographs were collected with an image pixel size of 0.84 Å 
and a defocus range of −1.5 to −2.5 m. For hTRPV6 in the absence 
of inhibitors, 5732 micrographs were collected with an image pixel 
size of 0.84 Å and a defocus range of −1.0 to −2.0 m.
Images of frozen-hydrated particles of hTRPV6 in the presence 
of 30, 3OG, or Br-cis-22a were collected on a Polara 300 kV TEM 
(FEI) with a Schottky field emission gun, cartridge loading system, 
and a Gatan K3 Summit DED camera (Gatan, Pleasanton, CA, USA). 
For hTRPV6 in the presence of Br-cis-22a, 5787 micrographs were 
collected in counting mode with an image pixel size of 0.95 Å across 
a defocus range of −1.5 to −3.5 m. The total dose of ~71 e− Å−2 was 
attained by using a dose rate of ~16 e− pixel−1 s−1 across 40 frames 
for 4 s of total exposure time. For hTRPV6 in the presence of 30 and 
3OG, 6362 and 7626 micrographs were collected, respectively.
Image processing and 3D reconstruction
All datasets were processed in RELION (50) and/or cryoSPARC 
(see table S2 for details) (51). Movies were motion-corrected with 
either MotionCor2 (52) algorithm implemented in RELION (50) or 
cryoSPARC’s built-in patch motion correction (51). Contrast transfer 
function (CTF) estimation was performed on non–dose-weighted 
micrographs using Gctf (53) or patch CTF estimation in cryoSPARC 
(51). Subsequent data processing was done on dose-weighted mi-
crographs. Following CTF estimation, micrographs were manually 
inspected, and those with outliers in defocus values, ice thickness, 
and astigmatism as well as micrographs with lower predicted CTF- 
correlated resolution (>6 Å) were excluded from the rest of the pro-
cessing pipeline (individually assessed for each parameter relative 
to overall distribution; no set threshold). For this curation, in the 
case of datasets processed in cryoSPARC (51), the exposure curation 
module was used. Particles were picked (i) manually (in RELION) 
or (ii) using cryoSPARC’s blob picker and, in both cases, further 
classified into two-dimensional (2D) classes. A selection of 2D 
classes was used to generate templates for template-based picking. 
Picked particles were further 2D- and 3D-classified in iterative clas-
sification and selection rounds. 3D-selected classes were used for 
3D template generation and refinement. The reported resolutions 
of the final maps were estimated using the gold standard Fourier 
shell correlation (GSFSC) in cryoSPARC (51). The local resolu-
tion predictions were calculated in cryoSPARC (51), with the reso-
lution range estimated using FSC = 0.143 criterion (50). EM den-
sity visualization was done in UCSF (University of California at San 
Francisco) Chimera (54).
As a representative of the image processing workflow, data for 
hTRPV6 in the presence of cis-22a were processed as follows (see 
also fig. S3). Initially, 1695 particles were manually picked in RELION 
(50) to generate 2D classes that were subsequently used as templates 
to automatically pick a total of 1,593,044 particles. These particle 
images were imported into cryoSPARC (51) for three iterative 
rounds of 2D classification and 2D class selection, i.e., with manual 
selection of 2D classes between classification rounds to further re-
classify the selected classes. The particle images from the final 2D 
selection (329,613 particles) were subjected to 3D classification 
(heterogeneous refinement in cryoSPARC) into four classes with no 
symmetry imposed using a box- and pixel-size–corrected, previously 
published 3.9-Å cryo-EM map of hTRPV6 (EMD-8961) (30) as 
template volume. Particles from three resulting classes (279,260 in 
total) were pooled together and refined with the C4 symmetry using 
cryoSPARC’s homogeneous refinement, with the imported volume 
(EMD-8961) as a template, to a 3.19-Å-resolution map. The particle 
stacks were CTF-refined and then used together with the 3.19-Å 
map as a template in another round of homogeneous refinement 
with imposed C4 symmetry to reach a 3.13-Å-resolution map. The 
same particles were then subjected to a final round of 3D classifica-
tion into four classes with C4 symmetry using the 3.13-Å map as 
well as lower-resolution volumes from intermediate 3D homoge-
neous and heterogeneous refinements as templates to separate par-
ticles of different quality. The largest of the resulting four 3D classes 
(199,015 particles) was homogeneously refined with C4 symmetry 
using the generated volume from the heterogeneous refinement 
(3.67 Å map) as template to 3.10 Å.
Model building
To build models of TRPV6 in the absence or presence of PCHPDs 
in Coot (47), we used the previously published crystal or cryo-EM 
structures of TRPV6 as guides (27, 31). The models were tested for 
overfitting by shifting their coordinates by 0.5 Å (using shake) in 
Phenix (46), refining each shaken model against a corresponding 
unfiltered half map, and generating densities from the resulting 
models in Chimera. Structures were visualized, and figures were 
prepared in UCSF Chimera (54) and PyMOL (46).
MD simulations
The 3D structure of cis-22a bound to hTRPV6-CtD reported here 
was used for MD simulations. The files containing the atomic co-
ordinates of cis-22a bound to hTRPV6-CtD were embedded in a 
dipalmitoyl phosphatidylcholine (DPPC) bilayer solvated with sim-
ple point charge (SPC) water and 0.15 M NaCl (55). The bilayer and 
lipid parameters were downloaded from the web server (http://
wcm.ucalgary.ca/tieleman/downloads). To fully embed the struc-
tures of the hTRPV6-CtD tetramer on the downloaded lipid bilayer, 
we used genconf –nbox implemented in Gromacs 2020.1 (56) to 
expand the lipid box through X and Y. The starting system for MD 
simulations was also assembled with Gromacs 2020.1. For packing 
lipids around an embedded protein, we used the script InflateGRO 
(57), manually removing the overlapping lipids. For the tetramer- 
bound system, wherein cis-22a was only retained in the LBS-2 sites, 
the box dimensions had 12.8 × 12.8 × 12.8 Å, the hTRPV6-CtD 
tetramer, 4 cis-22a molecules, 335 DPPC molecules, 41,026 SPC 
water molecules, 207 sodium ions, 191 chloride ions, totaling 
165,574 atoms. For the pore-bound system, wherein the cis-22a was 
only retained in the pore site, the box dimensions had 12.8 × 12.8 × 
12.8 Å, the hTRPV6-CtD tetramer, 1 cis-22a molecule, 335 DPPC 
molecules, 41,015 SPC water molecules, 210 sodium ions, 191 chlo-
ride ions, totaling 165,379 atoms.
MD simulations were run using Gromacs 2020.1 with a time 
step of 2 fs for computation and GROMOS96 53A6 force field, ex-
tended to include Berger lipid parameters (58). Initial parameters 
for cis-22a were obtained from the Automated Topology Builder 
web server (https://atb.uq.edu.au/). The system was first energy- 
minimized using steepest descent for 1000 steps with position re-
straints on all protein atoms, ligands, and lipids. Then, another 
three steps of energy minimization were consecutively followed by 
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removing the restraint over lipids, ligand, and lastly protein. After 
energy minimization, 5 ns of isochoric-isothermal (NVT) simula-
tion with position restraint on all protein and ligand atoms was per-
formed at 323 K. The isobaric-isothermal (NPT) equilibration was 
performed in four steps, consisting of gradually decreasing the po-
sitional restraints on the heavy atoms of protein and ligand. First, 
the system was equilibrated for 5 ns with position restraint on all 
protein and ligand atoms, at 323 K, then the position restraint was 
switched to protein backbone and all ligand atoms for 5 ns, then the 
system was equilibrated for 5 ns with restraints over ligands, and the 
temperature was switched to 303 K. The last step of NPT equilibra-
tion was performed in 5 ns without restraints. The 25-ns production 
run was also performed without restraints. During the equilibra-
tion, system pressure was 1 bar, using velocity rescale (59) for tem-
perature coupling and Parrinello-Rahman barostat for pressure 
coupling. Semi-isotropic pressure coupling was used during simu-
lation. All bounds involving hydrogen atoms were constrained 
using LINCS algorithm. Short-range nonbonded interactions were 
cut at 12 Å. Long-range electrostatic interactions were computed 
using particle mesh Ewald summation with a Fourier grid spacing 
of 1.6 Å. The production run was performed with the same parame-
ters as described above but with the thermostat switched to Nose-
Hoover (60).
The resulting production trajectories were analyzed using VMD 
(61), and PyMOL was also used to generate the images. RMSDs of 
the protein C atoms and cis-22a heavy atoms were calculated fol-
lowing superposition of residues of each tetramer subunit onto the 
coordinates of the energy-minimized structure.
Cadmium influx assay (FLIPR)
Molecular biology
The hTRPV6 mutants were constructed by site-directed mutagene-
sis (SDM) of hTRPV6 pIRES2 DsRed-Express2 or TagRFP-hTRPV6 
pTagRFP-C1 construct using Pfu Turbo DNA polymerase (Agilent 
Technologies). The forward mutagenesis primers used for SDM were 
synthesized by Microsynth AG (Balgach, Switzerland). The reverse 
complementary of the primers was used as the reverse mutagenesis 
primers. The correct clones were verified by Sanger sequencing 
(Microsynth AG).
hTRPV6 functional assay on FLIPR
HEK 293 cells (ATCC CRL-3216) were seeded at a density of 30,000 cells 
per well on poly-d-lysine (P6407, Sigma-Aldrich)–coated Corning 
96-well black polystyrene clear bottom microplates (CLS3603, Sigma- 
Aldrich) in 100 l of phenol red–free Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% FBS without antibiotics. 
The cells were cultured at 37°C and 5% CO2 until 80 to 90% confluent 
(16 to 20 hours), after which they were transfected with 200 ng of plasmid 
DNA (wild-type or mutant hTRPV6) per well using Lipofectamine 
2000 (11668019, Thermo Fisher Scientific).
One vial of calcium indicator, calcium-5 (R8186, Molecular De-
vices LLC), was reconstituted with 10 ml of nominally calcium-free 
(NCF) modified Krebs buffer containing 117 mM NaCl, 4.8 mM 
KCl, 1 mM MgCl2, 10 mM d-glucose, and 10 mM Hepes (pH 7.5). 
Sixteen to 18 hours after transfections, cells were washed with NCF 
Krebs buffer (250 l per well) and loaded (90 l per well) with NCF 
Krebs buffer containing 50 l of reconstituted calcium-5 indicator 
per milliliter of buffer. Following 1-hour incubation at 37°C in the 
dark, fluorescence measurements were carried out using a fluoro-
metric imaging plate reader, FLIPR Tetra (Molecular Devices, LLC), 
to assess the effect of different mutations or inhibitors on TRPV6 
channel function. During the FLIPR assay, the cells were illuminated 
using a 470- to 495-nm light-emitting diode module, and the emitted 
fluorescence signal was filtered with a 515- to 575-nm emission fil-
ter. After recording a 50-s baseline, 10 l of 10X (X, final concentra-
tion) TRPV6 inhibitor dissolved in NCF Krebs buffer was robotically 
administered to the cells. Cells were incubated, and fluorescence 
was monitored in the presence of the inhibitor for a total of 10 min 
before the administration of 100 M (2X) CdCl2 dissolved in NCF 
Krebs buffer. The fluorescence was monitored for another 5  min 
after administration of CdCl2. The fluorescence signals were ana-
lyzed using the ScreenWorks 3.1.1.8 software (Molecular Devices 
LLC). The TRPV6-mediated Cd2+ influx was quantified by calculat-
ing the area under the curve (AUC) of the fluorescence intensity 
traces, following administration of the final 50 M CdCl2. The 
AUC of the empty vector–transfected cells was used for background 
subtraction. Data from at least two independent experiments are 
presented. The Br-cis-22a dose-response curves were generated 
(nine-point curve, six repeats per concentration, twofold serial dilu-
tion starting at 10 M), and the IC50 values were extrapolated from 
these plots for each compound (GraphPad Prism, version 5.0). In-
hibition curves were obtained by nonlinear regression using the 
built-in log[inhibitor] versus response variable-slope function (four 
parameters).
Electrophysiology
Cell culture, construct, and molecular biology
HEK 293 cells were cultured in DMEM supplemented with 10% fetal 
calf serum, penicillin (100 U/ml), and streptomycin (100 g/ml) at 
37°C under humidified atmosphere containing 5% CO2, as previ-
ously described. The cells were transiently transfected 24 hours be-
fore the experiments with human or rat TRPV6 N-terminally tagged 
with eYFP (enhanced yellow fluorescent protein) (peYFP vector) 
using TransFectin Lipid reagent (Bio-Rad). The endogenous TRPV6 
protein in human comprises an extended N terminus (765 amino 
acids); however, for all experiments in this publication, the truncated 
version (725 amino acids) of the TRPV6 channel was used. Muta-
tions in hTRPV6 (N464L, R470A, Q483A, F504Y, W583F, R470A, 
and W583F) were generated using the QuikChange XL SDM kit 
(Stratagene) and were confirmed by sequencing.
Electrophysiological recordings
Patch-clamp experiments were conducted in the whole-cell config-
uration at r.t. (20° to 24°C) with an Ag/AgCl reference electrode. 
Voltage ramps ranging from −90 to +90 mV over a time period of 
200 ms were applied every 5 s from the holding potential of 50 mV. 
For the time courses, the inward current density was recorded 
at −74 mV. The internal pipette solution contained the following: 
145 mM Cs-methanesulfonate, 8 mM NaCl, 5 mM MgCl2, 10 mM 
Hepes, and 20 mM EGTA (pH 7.2). The extracellular solution 
(10 mM Ca2+) consisted of 145 mM NaCl, 5 mM CsCl,1 mM MgCl2, 
10 mM Hepes, 10 mM glucose, and 10 mM CaCl2 (pH 7.4). The 
DVF solution comprised 150 mM NaCl, 10 mM Hepes, 10 mM glu-
cose, and 10 mM EDTA (pH 7.4). The currents were leak-corrected 
by subtraction of the remaining leak currents after 100 M or 1 mM 
LaCl3 block. The liquid junction potential was determined as 12 mV; 
the voltages were not adjusted. All experiments were conducted for 
a minimum of two different experimental days. Application of the 
same amount of DMSO in 10 mM Ca2+ solution as in the inhibitor- 
containing solution was used as a control. Statistical analyses and 
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graphs (means ± SEM) were done using the OriginPro software 
(version 9.1, for Windows, OriginLab). The results were assumed to 
follow the normal distribution, and the hypothesis testing was per-
formed using either two-sided Student’s paired or unpaired t tests, 
Wilcoxon signed-rank tests (two-sided), or Mann-Whitney U tests. 
* indicates significance (P value < 0.05); ns stands for “not signifi-
cant.” Dose-response curves were fitted with the Hill equation, and 
the extent of calcium-dependent inactivation was measured as the 
current amplitude reduction after 180 s since the beginning of cal-
cium application relative to the maximum current amplitude.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/48/eabe1508/DC1
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